ReviewFrontiers in oncology2016
The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations.
Review in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.BMC medical genetics · 2018Pooled it
- Lesion detection by [European journal of nuclear medicine and molecular imaging · 2019Trial
- Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [Molecular imaging and biology · 2019Trial
- Imaging response assessment in metastatic renal cell carcinoma: a radiologist's guide to contemporary therapeutic strategies.Abdominal radiology (New York) · 2026Review
- Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Rare renal metastasis: Oligometastatic non-small cell lung cancer diagnosed with ultrasound guided renal biopsy.Radiology case reports · 2026Article
- Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions.Cancers · 2026Review
- Review
- SpecificTheranostics · 2026Article
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
- A case of pancreatic metastatic tumor of renal cell carcinoma positive for somatostatin receptor scintigraphy.Clinical journal of gastroenterology · 2025Article
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- Article
- Diagnostic and prognostic role ofEJNMMI research · 2025Article
- The Utility ofMolecular imaging and radionuclide therapy · 2025Article
- Clear cell renal carcinoma metastasis to the thyroid gland combined with papillary thyroid carcinoma - a case report.Frontiers in oncology · 2025Article
- Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma.BMJ oncology · 2025Review
- Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored byPharmaceutics · 2024Article
- Efficacy ofJapanese journal of radiology · 2024Article
- Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.Materials today. Bio · 2024Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike for most other malignancies, application of FDG PET/CT is limited for renal cell carcinoma (RCC), mainly due to physiological excretion of 18F-fluoro-2-deoxy-2-d-glucose (FDG) from the kidneys, which decreases contrast between renal lesions and normal tissue, and may obscure or mask the lesions of the kidneys. Published clinical observations were discordant regarding the role of FDG PET/CT in diagnosing and staging RCC, and FDG PET/CT is not recommended for this purpose based on current national and international guidelines. However, quantitative FDG PET/CT imaging may facilitate the prediction of the degree of tumor differentiation and allows for prognosis of the disease. FDG PET/CT has potency as an imaging biomarker to provide useful information about patient's survival. FDG PET/CT can be effectively used for postoperative surveillance and restaging with high sensitivity, specificity, and accuracy, as early diagnosis of recurrent/metastatic disease can drastically affect therapeutic decision and alter outcome of patients. FDG uptake is helpful for differentiating benign or bland emboli from tumor thrombosis in RCC patients. FDG PET/CT also has higher sensitivity and accuracy when compared with bone scan to detect RCC metastasis to the bone. FDG PET/CT can play a strong clinical role in the management of recurrent and metastatic RCC. In monitoring the efficacy of new target therapy such as tyrosine kinase inhibitors (TKIs) treatment for advanced RCC, FDG PET/CT has been increasingly used to assess the therapeutic efficacy, and change in FDG uptake is a strong indicator of biological response to TKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.